Fifteen out of 18 "pink and puffing" patients completed a double-blind, placebo-controlled cross-over trial of diazepam and promethazine for breathlessness and reduced exercise tolerance. Dosages were 25 mg and 125 mg daily, respectively, and each course lasted two weeks. Patients with psychiatric or other major medical histories were excluded.
Introduction
Breathlessness and limitation of exercise tolerance in patients with chronic bronchitis and emphysema are variable and do not correlate well with abnormalities of lung function' or with the pathological findings at necropsy.2 Among patients with fixed airways obstruction the "pink and puffing" type maintain a low or normal arterial carbon dioxide pressure (Paco,) and a nearly normal oxygen pressure (Pao,) at the expense of extreme breathlessness. [3] [4] [5] Since attempts at improving lung function are relatively ineffective, there is a place for a safe remedy to relieve breathlessness.3 6 Preliminary studies indicated that diazepam might produce symptomatic relief of breathlessness and improvement of exercise tolerance in pink and puffing patients without altering resting blood gas values.7 Promethazine (a sedating antihistamine) may have an effect on exercise-induced breathlessness in normal subjects, whereas diazepam does not (R D Stark and S A Gambles, paper presented at, SEPCR conference on breathlessness, Sheffield, August 1980; Clin Sci, in press). We have therefore conducted a randomised, doubleblind placebo-controlled trial comparing the effects of diazepam and promethazine on breathlessness and exercise tolerance in 18 pink puffers. Including a second sedating drug made the trial more effectively blind.
Patients and methods
Eighteen patients (15 men) with severe chronic airways obstruction, moderate or severe breathlessness, and normal or low Paco, entered the trial (table I) . Patients with a current or past psychiatric or other major medical history were excluded. Of the nine patients aged over 65, four had retired prematurely owing to breathlessness. Of the nine patients aged under 65, seven were unable to work because of breathlessness and two were in sedentary occupations. All patients had smoked cigarettes (mean 416 pack-years, range 10-160 pack-years), though all had stopped smoking (mean 4-3 years before, range 6 months to 20 years), usually at the onset of breathlessness (51 years before, range 2-20 years). Thirteen patients had recently lost weight (mean current weight 56 4 kg, mean previous highest 62-2 kg).
Patients received diazepam 5 mg thrice daily and 10 mg (two tablets) at night, promethazine 25 mg thrice daily and 50 mg (two tablets) at night, or matched placebo over three consecutive two-week periods in a double-blind cross-over design. The treatments were given in randomised order. Any sedative drugs were withdrawn two weeks before the study. Patients were advised against driving, operating machinery, and drinking alcohol. Tablets were counted to ensure that correct dosages had been taken. Twice before the trial (practise and baseline) and at the end of each treatment period patients underwent the following investigations as day patients.
Respiratory measurements comprised peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC).
The London Chest Hospital, London E2 9JX, and Brompton Hospital, (fig 1) . A similar trend towards improvement was assessed by oxygen-cost diagram and daily visual analogue scores, though these did not achieve significance. Patients were significantly more drowsy when taking diazepam than when taking placebo. There was no significant difference in drowsiness between the placebo and promethazine periods or in anxiety and depression scores with any treatment.
Breathlessness-When individual breathlessness scores in each patient achieved with promethazine and diazepam were compared with those during the placebo period (sign test) there was a reduction in breathlessness after promethazine but no significant difference in breathlessness between the diazepam and placebo periods (promethazine < placebo = diazepam; p < 0001) (fig 2) treadmill; total work load on bicycle ergometer; maximal ventilation) but did not achieve statistical significance. There were no significant changes with any treatment in resting ventilation, alveolar-arterial gas exchange, arterial desaturation, or metabolic gas exchange. Resting blood gas tensions and maximal exercise Pao, were unchanged but maximal exercise Paco2 was significantly higher during the diazepam period than during the placebo or promethazine period.
Discussion
Breathlessness is a major symptom of chronic lung disease and is often more distressing than the limitation of exercise tolerance. This is particularly so in pink and puffing patients with fixed airways obstruction, who maintain nearly normal blood gas tensions for many years at the cost of persistent breathlessness. Treatment aimed at improving lung function is largely ineffective and we therefore aimed for symptomatic relief of breathlessness. Attempts at symptomatic improvement with carbimazole'6 and beta, blockade'7 were unsuccessful, and we were therefore encouraged by the preliminary work of Mitchell-Heggs et al,7 which suggested that diazepam in the doses used in our study might reduce breathlessness and improve exercise tolerance in four pink and puffing patients.
Stark and Gambles (SEPCR conference on breathlessness, Sheffield, August 1980), who used similar methods to ours for assessing breathlessness by visual analogue scale in normal subjects exercising on a treadmill, reported that promethazine 25 mg in a single oral dose may reduce breathlessness but that oral diazepam 10 mg was ineffective. In our study diazepam caused a significant deterioration in exercise tolerance and had no effect on breathlessness at fixed work loads when compared with placebo. This is contrary to the findings of MitchellHeggs et al,7 who reported a "striking reduction in dyspnoea and improvement in exercise tolerance." Two of their patients had early dementia, however, and one was depressed. Any improvement of breathlessness in a group of psychologically disturbed patients treated with an anxiolytic drug must be interpreted with caution. We deliberately excluded patients with a history of psychiatric illness. Mitchell-Heggs et al also compared diazepam with placebo in an uncontrolled manner. It is impossible to blind the sedative effect of diazepam against placebo alone and we included a second sedating drug to make the trial effectively double-blind. In addition to reducing exercise tolerance, considerable morbidity was associated with diazepam. The only death during the study occurred when the patient with the worst pulmonary function was taking diazepam. Although the patient was tachypnoeic immediately before death, we cannot exclude the possibility that an inappropriate reduction in respiratory drive contributed to death. The use of diazepam in airways obstruction should be limited strictly to those few patients with extreme anxiety and low Paco,.
We found a small but significant reduction in breathlessness and improvement in exercise tolerance with promethazine when compared with placebo. This was achieved without significant alteration of lung function or resting and exercise blood gas tensions. While we cannot completely exclude a small change in lung function, these results tend to confirm the suggestion that promethazine reduces the feeling of breathlessness. Many patients did complain of drowsiness while taking promethazine but this did not achieve statistical significance over the whole group, and only one dosage reduction was made during a promethazine period. Further investigation will find the dosage of promethazine that offers the maximum benefit with the least side effects, and other antihistamines must be studied.
We conclude that promethazine is beneficial for breathlessness and exercise tolerance in pink and puffing patients with fixed airways obstruction and does not alter lung function; but these benefits are slight and must be weighed against the disadvantages of drowsiness, which may be a problem in some patients. Diazepam failed to produce any benefit and, indeed, may be positively harmful and is contraindicated in patients with airways obstruction unless there is severe anxiety and a low Paco,. 
Case reports
Case 1-A 33-year-old woman was admitted after prolonged abuse of Parstelin (tranylcypromine 10 mg, trifluoperazine 1 mg), culminating in an overdose of 40 tablets. Though initially lucid, 24 hours later she became hallucinated, confused, agitated, and aggressive. Over the next eight days she returned to normal. She had first suffered from depression at the age of 15, and had since had continuous psychiatric treatment. Personality disorder and depression were diagnosed. At the age of 25 Parstelin was started and before long she was taking 30 tablets daily. On at least two occasions she developed severe thrombocytopenic purpura due to the Parstelin abuse. All attempts at withdrawal from the drug were only temporarily successful.
Case 2-A 34-year-old schoolteacher was admitted complaining of addiction to Parstelin. He was taking 15 tablets daily, but had had some difficulty obtaining the drug, getting prescriptions from many different doctors. He had a history of three previous admissions for anxiety, depression, and alcoholism. On abstaining from Parstelin he suffered headaches, diarrhoea, and weakness and felt unable to cope with work. He also abused chlordiazepoxide, taking about 100 mg daily. While We report a case of damage to the tricuspid valve during preoperative insertion of a Swann-Ganz catheter. The lesion was discovered by visual inspection during the operation, which suggests that the incidence of undetected damage and its complicationsl-3 might be greater than previously thought.
Case report
A 59-year-old woman with a history of rheumatic heart disease was admitted for elective aortic and mitral valve replacement and insertion of a tricuspid ring. Two months previously cardiac catheterisation had shown mixed mitral valve disease, predominantly stenosis and aortic insufficiency. The murmur of tricuspid incompetence could also be heard. Chest x-ray examination showed an enlarged left ventricle, right ventricle, and left atrium.
A pulmonary artery catheter was inserted for measurement of filling pressures and thermodilution cardiac outputs during the operation. A triple-lumen 7 FG flow-directed Swann-Ganz catheter (Instrumentation Laboratories) was inserted via the right cephalic vein in the antecubital fossa using a Cordis introducer. A cut-down had previously been performed on the right basilic vein, and the catheter was inserted at the right cephalic vein after failure to enter the chest using the left cephalic vein.
The catheter entered the chest easily, and as soon as it was in the superior vena cava the balloon was inflated and the pressure at the catheter tip
